||MN-201 is an orally administered vitamin D5 analog for the treatment of cancer. MN-201 is the first synthetic vitamin D5 receptor ligand (VDRL) to be advanced into clinical trials for a variety of cancers including breast, prostate and colon cancers. In preclinical studies, MN-201 demonstrated broad anti-tumor activity in cancer cells. In animal models, oral administration of MN-201 also resulted in anti-tumor activity including tumor regression in xenograft models of major solid tumor types. In contrast to treatment with other vitamin D(3) analogs and the naturally occurring vitamin D hormone, calcitriol, favorable anticancer effects with MN-201 were observed in the absence of significantly raised calcium levels.